Part of The Weill Cornell Graduate School of Medical Sciences. A combined program of Weill Cornell Medical College and the Sloan-Kettering Institute,we are a premiere school in Biomedical Research. We are part of Cornell University (Ithaca, NY) but Weill Cornell Medical College is located in New York City. Read more about our programs of study:

The research activities of the Cornell Pharmacology Program faculty cover broad areas of modern pharmacological sciences. Faculty carry out research in cancer pharmacology, neuropharmacology, cardiovascular pharmacology, drug metabolism, toxicology, proteomics, molecular pharmacology, receptors and signal transduction, and drug design.

POSTDOCTORAL RESEARCH:

OPPORTUNITIES AND INFORMATION



PHOTOGRAPHS:

PARTIES AND EVENTS

SPRING RETREAT

GRADUATION

JANUARY 30, 2018
Anthony Sauve, Ph.D.
Title: "Necessary and Augment if Depleted: The challenge and promise of targeting a central metabolic factor for therapeutic effect"
4:00PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Lorraine J. Gudas


FEBRUARY 13, 2018
Kenneth A. Jacobson, Ph.D.
Title: “Structures of G Protein-Coupled Purine Receptors Enable Drug Discovery”
4:00PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Arleen Rifkind and Ryan Serio


FEBRUARY 27, 2018
Wendy V. Gilbert, Ph.D.
Title: “Regulated mRNA modification: A new function for ancient RNA modifying enzymes”
4:00PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Samie Jaffrey


MARCH 13, 2018
Scott Waldman, M.D.
REIDENBERG LECTURE
Title: “Paracrine hormone hypothesis of colorectal cancer”
4:00PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Marcus Reidenberg


MARCH 27, 2018
Marcia Haigis, Ph.D.
Title: “Mitochondria in Health and Disease”
4:00PM - 5:00PM
Lecture Hall Room: A-250
Host: Dr. Steven Gross and Dr. Anthony Sauve


Text size:

February 9, 2018:

Dr. Qing Miao Receives 2-Year Fellowship from the Prevent Cancer Foundation.

Qing Miao, Postdoctoral Associate in Pharmacology, Weill Cornell Medical College, has been awarded a 2-year fellowship from the Prevent Cancer Foundation. Dr. Miao’s project – to identify new strategies for more effective retinoid-based cancer prevention in Head and Neck Squamous Cell Carcinoma – was selected for funding after a rigorous review by the Foundation. Dr. Miao works in the laboratory of Dr. Lorraine Gudas.

Head and Neck Squamous Cell Carcinoma (HNSCC) is the seventh most common cancer worldwide. Surgery is the preferred treatment for early stage HNSCC. However, aggressive local invasion and metastasis lead to a high recurrence rate, which makes HNSCC a challenging disease to treat. To this end, prevention of HNSCC is an important goal.

The project, which began in January 2018, builds on existing research that has shown that one type of retinoid (vitamin A derivative) drug can prevent tumor formation in a mouse model of this cancer. Dr. Miao proposes that a combination of retinoids will have greater cancer preventive effect. Retinoids include vitamin A and related molecules. 13-Cis-RA, a retinoid, can reverse premalignant lesions and prevent the development of second primary tumors in head and neck cancers because of its ability to restore normal cell growth and differentiation. The lab uses a carcinogen to induce HNSCC tumors in mice, and has shown that the synthetic retinoid CD1530 effectively prevents the development of oral tumors in the mice. AC261066 is another synthetic retinoid drug that has been identified in the laboratory. AC261066 may also have cancer preventive effects in HNSCC because its target protein is a purported tumor suppressor. Dr. Miao’s hypothesis is that AC261066, in combination with CD1530, will prevent the induced HNSCC tumor formation with greater efficacy than either drug alone. Collectively, this research has the potential to identify new strategies for more effective retinoid-based cancer prevention in HNSCC. These findings should save lives by preventing cancer in high-risk individuals.


January 11, 2018:

The first lecture, given by Dr. Ignacio Rodriguez, of the “From Molecule to Prescription” Drug Development PhD course was outstanding. Here is a picture of the class. Postdocs and faculty are most welcome to sit in on lectures! For a link to the syllabus, click here: click here


December 12, 2017:

Dr. Anthony Sauve's research on NAD was recently featured in the December 2017 issue of SHAPE magazine! To read more: click here

November 16, 2017:

Dr. John Blenis, his postdoc Gina Lee, and colleagues just published a paper in Cell on a new signaling pathway that regulates fat production. Congratulations! For more information: click here

November 13, 2017:

PhD student Shira Yomtoubian (PI, Dr. Mittal) won first prize in the school-wide 3 Minute Thesis presentation. Congratulations!

November 9, 2017:

Here is the syllabus listed under Quarters III & IV, of the new graduate school course in Drug Development starting in January 2018: click here

ALUMNI NEWS (Est. 10/2015):

CLICK HERE

December, 2017:

Lorraine Gudas connected with Sara DiNapoli, Julia Silveira, & Emily Mercer at a holiday party!. Emily (PhD awarded last year in Pharmacology) is now working at the healthcare co. IQVIA in NYC.